Saliva Irisin Level is Higher and Related With Interleukin 6 in Generalized Periodontitis

Periodontitis Clinical Trial

Official title:

Saliva Irisin Level is Higher and Related With Interleukin 6 in Generalized Periodontitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05474820
• Other study ID #: 361
• Status: Completed
• Phase: N/A
• Start date: February 24, 2022
• Est. completion date: July 19, 2022

Study information

• Verified date: July 2022
• Source: Istanbul Medipol University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Irisin is novel adipomyokine known as a mediator of physical activity that produced mainly by skeletal muscle and adipose tissues. It is cleaved from the fibronectin type III domain-containing protein 5 (FDNC5), which is, in turn, induced by peroxisome proliferator-activated receptor-ɣ co-activator 1-α (PGC-1α). Several studies reported that irisin is related with pathogenesis of many diseases which are known to be associated with periodontal disease such as obesity, diabetes mellitus, rheumatoid arthritis, cardiovascular disease, nonalcoholic fatty liver disease and metabolic bone diseases. There are several studies those have reported that increased IL-6 levels are associated with progression and severity of periodontitis . Recently, it has been shown that irisin is expressed in human periodontal ligament cells (hPDL), dental pulp stem cells and osteoblasts. Also, a few studies revealed that irisin promotes growth, migration and matrix formation in hPDL cells and cementoblast differentiation. To the best our knowledge, there 's one study has been reported that the higher levels of irisin in saliva in patient with chronic periodontitis

Description:

Twenty systemically healthy subjects with healthy periodontium and 20 patients with stage III grade B generalized periodontitis were enrolled for this cross-sectional study. The study was performed in accordance with the Helsinki Declaration of 1975, as revised in 2013. Before starting, the informed consent was obtained from all participants which was approved by the human subject's ethics board of Istanbul Medipol University's Faculty of Dentistry for use and access of human subjects in research.For all study subjects, the exclusion criteria were (1) use of contraceptive drugs; (2) use of antibiotics, anti-inflammatory drugs, or immunosuppressants in the last 3 months before the study; (3) alcohol consumption; (4) pregnancy or breastfeeding; (5) taking drugs that could cause side effects such as gingival hypertrophy or hyperplasia; and (6) any periodontal treatments in the 3 months prior to enrollment. All participants were systemically healthy and non-smokers (never smokers).The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient .For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. The minimum detectable doses of irisin and IL-6 for saliva with these assay kits were 1,28 and 13,22 pg/ml, respectively. For serum, minimum detectable irisin dose was 175,43 whereas IL-6 was 0,06 pg/ml. All samples were run in duplicate, and values have been averaged.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 19, 2022
• Est. primary completion date: June 20, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• systemically healthy
• clinical diagnosis of periodontitis
• clinical diagnosis of periodontal health Exclusion Criteria: *history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months)
• nonsurgical periodontal treatment (previous 6 months)
• surgical periodontal treatment (previous 12 months)
• presence of<10 teeth
• current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy)
• diabetes
• diagnosis of rheumatoid arthritis
• pregnancy
• lactating
• smoking
• excessive alcohol consumption.

Related Conditions & MeSH terms

• Inflammatory Response
• Periodontitis

Intervention

Other:
• Samples collection and ELISA analyses
The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min. For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged.

Diagnostic Test:
• Evaluating periodontal paramètres
The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient

Locations

Country	Name	City	State
Turkey	Istanbul Medipol University, School of Dentistry	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Medipol University Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Pullisaar H, Colaianni G, Lian AM, Vandevska-Radunovic V, Grano M, Reseland JE. Irisin promotes growth, migration and matrix formation in human periodontal ligament cells. Arch Oral Biol. 2020 Mar;111:104635. doi: 10.1016/j.archoralbio.2019.104635. Epub 2019 Dec 16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pocket probing depth	Measurement of the depth of a sulcus or periodontal pocket determined by measuring distance from a gingival margin to the base of the sulcus or pocket with a calibrated periodontal probe.	3 months
Primary	Clinical attachment level	Clinical attachment level (or loss, CAL) is a more accurate indicator of the periodontal support around a tooth than probing depth alone. CAL is measured from a fixed point on the tooth that does not change, the CEJ.; To calculate CAL, two measurements are needed: distance from the gingival margin to the CEJ and probing depth.; In recession: probing depth (+) gingival margin to the CEJ (add). In tissue overgrowth: probing depth (-) gingival margin to the CEJ (subtract)	3 months
Secondary	Saliva and serum samples processing and analyses	Saliva and serum samples obtained for each patient were used for cytokine analysis. Prepared samples were analyzed for Irisin and IL-6 via ELISA kits.	1 month